Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYRPC8)

Drug Name

RVSVIN HIV-1 gag vaccine Drug Info

Synonyms

RVSVIN HIV-1 gag vaccine, Profectus Biosciences; RVSV vector-based HIV-1 vaccine, Profectus BioSciences; Recombinant VSV vector-based HIV-1 vaccine, Profectus BioSciences; Recombinant vesicular stomatitis virus vector-based HIV-1 vaccine, Profectus BioSciences

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMYRPC8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human immunodeficiency virus GAG protein (HIV gag)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bevirimat	DML2D8Q	Human immunodeficiency virus infection	1C62	Phase 2	[3]
LIPO-5	DMWY0V1	Human immunodeficiency virus infection	1C62	Phase 2	[4]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[5]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[5]
TBC-M4	DM9CDPO	Human immunodeficiency virus infection	1C62	Phase 1	[6]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[7]
PA-1050040	DMF4KPM	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[8]
Gem 92	DM4ZDVY	Human immunodeficiency virus-1 infection	1C62	Discontinued in Phase 1	[9]
MPC-9055	DMCMNKV	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[10]
MPI-461359	DMAVD4Q	Human immunodeficiency virus infection	1C62	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus GAG protein (HIV gag)	TTFGZB6	GAG_HV1H2	Not Available	[2]

------------------------------------------------------------------------------------

References

1	Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice. J. Virol. January 2008 vol. 82 no. 1 207-219.
2	Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81.
3	Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
4	HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
5	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
6	A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
7	Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
8	US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections.
9	Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3.
10	New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087.
11	Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63.